Full-Time
Senior Specialist
Digital Health Operations
Posted on 9/27/2025
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
No salary listed
High Wycombe, UK
In Person
Remote work options may be considered on a case-by-case basis.
 Medical, Clinical & Veterinary (1) |
|---|
- A minimum of a Bachelor degree is required. An advanced degree is preferred.
- 4+ years operational experience in clinical trials with a pharmaceutical company and/or a Clinical Research Organization is required.
- Demonstrated knowledge of clinical development processes, global clinical operations, and strategic planning is required.
- Familiarity with industry best methods for vendor management is required.
- Good understanding of the therapeutic areas where Johnson & Johnson is involved is required.
- Strong project management skills and presentation skills with the ability to lead a team independently is required.
- Strong verbal and written communication skills are required.
- Serving as a subject matter expert for Digital Health, providing advice/recommendation to study teams regarding the supplier(s) and device/technology alternatives.
- Completing Requests for Proposal documentation, and recommending appropriate suppliers to support study needs.
- Providing leadership and expertise for the completion of supplier specification development and set-up activities through lifecycle of the trial.
- Leading cross-functional study teams through changes of scope for Digital Health, providing technical expertise on the change of scope, assessment of risk, oversight of system requirements updates and user acceptance testing.
- Assisting in the resolution of issues escalated by study teams for processes owned, as well as cross-team specific issues under the supervision of the Digital Health Delivery Unit Lead.
- Assisting with inspection readiness activities as needed.
- Monitoring key performance indicators (KPIs) for services provided by suppliers.
- Conducting Lessons Learned sessions following the completion of study start-up activities, and as necessary, throughout other phases of the clinical development process.
- Effectively supporting the study team in close-out/deactivation of the Digital Health system and archive activities.
- Continually reviewing new emerging technologies focusing on efficiencies to be gained.
- Ensuring that principles of the Credo and Business Conduct Policy, Purchasing Code of Conduct, Healthcare Compliance and Ethical Code of Conduct of Pharmaceutical Medicine are used in supplier relationships.
- Experience with Digital Health Technology suppliers is preferred.
- Microsoft Project skills would be an advantage.
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Simplify's Take
What believers are saying
- CARVYKTI and RYBREVANT are driving near-term oncology growth.
- IMAAVY and CAPLYTA expand J&J into rare immunology and neuropsychiatry.
- The Firefly Bio acquisition adds a pan-KRAS oncology platform.
What critics are saying
- STELARA biosimilar erosion is already cutting a major immunology franchise.
- Firefly Bio's KRAS platform remains early and can fail clinically.
- AI surgery and Shockwave launches face adoption, reimbursement, and execution risk.
What makes Johnson & Johnson unique
- J&J focuses on Innovative Medicine and MedTech after spinning off Kenvue in 2023.
- Its portfolio spans oncology, immunology, neuroscience, cardiovascular, and surgical robotics.
- The company combines internal R&D with acquisitions like Abiomed, Shockwave, and Ambrx.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Johnson & Johnson who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -11%1 year growth
↓ -11%2 year growth
↓ -10%• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation
Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.
Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.
Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.
Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.